The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices.

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

FTC sues top PBMs for inflating insulin prices, accusing them of rigging competition and hurting patients. Legal action also includes GPOs.

Health-care company stocks fell as U.S. regulators look to crack down on prices and companies battle over market share of popular drugs. The Federal Trade Commission sued the drug middlemen that ...

Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...

The Federal Trade Commission brought action against the three largest prescription drug benefit managers (PBMs)—Caremark Rx ...